	US 11,766,444 B2
	Pharmaceutical composition for preventing or treating degenerative brain disorders including HDL-APOM-S1P as active ingredient
Jae Sung Bae, Daegu (KR); Hee Kyung Jin, Daegu (KR); Ju Youn Lee, Daegu (KR); and Min Hee Park, Daegu (KR)
Assigned to Kyungpook National University Industry-Academic Cooperation Foundation, Daegu (KR)
Appl. No. 16/634,460
Filed by Kyungpook National University Industry-Academic Cooperation Foundation, Daegu (KR)
PCT Filed Jul. 11, 2018, PCT No. PCT/KR2018/007857 § 371(c)(1), (2) Date Jan. 27, 2020, PCT Pub. No. WO2019/022412, PCT Pub. Date Jan. 31, 2019.
Claims priority of application No. 10-2017-0096223 (KR), filed on Jul. 28, 2017.
Prior Publication US 2021/0085697 A1, Mar. 25, 2021
Int. Cl. A61K 31/661 (2006.01); A61K 47/69 (2017.01); A61P 25/28 (2006.01)

CPC A61K 31/661 (2013.01) [A61K 47/6917 (2017.08); A61P 25/28 (2018.01)]

2 Claims

1. A method for treating Alzheimer's disease, the method comprising administering an effective amount of a composition comprising a high density lipoprotein (HDL-ApoM-S1P) in which apolipoprotein M is impregnated with sphingosine-1-phosphate as an active ingredient to an individual in need thereof.